HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beauty Bids Adieu To The Great Pioneer Estee Lauder

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder, the entrepreneur who created a cosmetics empire that helped define the American beauty industry, died April 24 at her home in Manhattan at the age of 97, according to the Estee Lauder Companies

You may also be interested in...



Estee Lauder

Three Lauder family trusts will sell 13 mil. shares of Class A Common Stock to "provide funds to pay estate taxes and meet other obligations" following the recent death of the company's Founding Chairman Estee Lauder (1"The Rose Sheet" May 3, 2004, p. 3). Public offering will consist of 11.3 mil. shares of Class A Common Stock and an additional 1.7 mil. shares "pursuant to an option to be granted to the underwriters," Goldman, Sachs & Co. and J.P. Morgan Securities, Inc., firm says in a May 18 announcement. A registration statement relating to the transaction has been filed with the Securities & Exchange Commission but has not yet become effective, company adds. Following the sale, the Lauder family will still hold 45.5% of outstanding common stock and 88.4% of combined voting power of the common stock...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel